Premium
Perioperative anidulafungin combined with triazole prophylaxis for the prevention of early invasive candidiasis in lung transplant recipients
Author(s) -
Sartain Emily,
Schoeppler Kelly,
Crowther Barrett,
Smith Joshua B.,
Abidi Maheen Z.,
Grazia Todd J.,
Steele Mark,
Gleason Terri,
Porter Krista,
Gray Alice
Publication year - 2021
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.13692
Subject(s) - medicine , perioperative , anidulafungin , echinocandin , cohort , incidence (geometry) , fluconazole , retrospective cohort study , clinical endpoint , surgery , caspofungin , antifungal , clinical trial , physics , dermatology , optics
Background Invasive candidiasis (IC) is a substantial cause of morbidity and mortality among lung transplant recipients (LTRs). Postoperative factors include prolonged hospital stay, central lines, delayed chest closure, and dehiscence increase IC risk. Correspondingly, current guidelines propose targeted IC coverage early posttransplant with fluconazole or an echinocandin. Methods This retrospective analysis was performed on LTRs from January 2016 to January 2020 and evaluated effectiveness of a recent protocol utilizing perioperative anidulafungin for early IC prevention in addition to long‐term triazole antifungal prophylaxis. Prior to this protocol, patients were primarily established on itraconazole prophylaxis alone. The primary endpoint was proven or probable IC within 90 days after transplant. Multivariable logistic regression modeling was used to assess risk factors for invasive fungal infection (IFI). Results Among 144 LTRs, there was a numerically lower incidence of IC in the protocol group, although not statistically significant (6% vs. 13%, p = 0.16). Incidence of proven or probable IFI was 7.5% in the protocol cohort and 19.5% in the pre‐protocol cohort ( p = 0.038). In multivariable analysis, when controlling for lung allocation score (OR 1.04, 95% CI 1.01–1.08), donor perioperative culture with fungal growth (OR 2.92, 95% CI 1.02‐8.92), and dehiscence (OR 3.54, 95% CI 1.14–10.85), protocol cohort was not significantly associated with IFI (OR 0.41, 95% CI 0.12–1.23). Conclusions To our knowledge, this is the first study investigating combination triazole/echinocandin use in the early post‐lung transplant period. These findings demonstrate that in‐hospital anidulafungin offers unclear benefit for early IC prevention when used in combination with triazole prophylaxis.